Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00334958 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00334958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00334958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 13, 2006
Completion date
May 20, 2009
Enrollment
356 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy